key: cord-0836963-nzg2rok6
authors: Rinewalt, Daniel; Coppolino, Anthony; Seethala, Raghu; Sharma, Nirmal; Salim, Ali; Keller, Steve; Mallidi, Hari R.
title: COVID‐19 patient bridged to recovery with veno‐venous extracorporeal membrane oxygenation
date: 2020-07-15
journal: J Card Surg
DOI: 10.1111/jocs.14829
sha: 0df5eab5e5d260e880cf6b17e97731825357d080
doc_id: 836963
cord_uid: nzg2rok6

BACKGROUND: In severe cases, the coronavirus disease 2019 (COVID‐19) viral pathogen produces hypoxic respiratory failure unable to be adequately supported by mechanical ventilation. The role of extracorporeal membrane oxygenation (ECMO) remains unknown, with the few publications to date lacking detailed patient information or management algorithms all while reporting excessive mortality. METHODS: Case report from a prospectively maintained institutional ECMO database for COVID‐19. RESULTS: We describe veno‐venous (VV) ECMO in a COVID‐19‐positive woman with hypoxic respiratory dysfunction failing mechanical ventilation support while prone and receiving inhaled pulmonary vasodilator therapy. After 9 days of complex management secondary to her hyperdynamic circulation, ECMO support was successfully weaned to supine mechanical ventilation and the patient was ultimately discharged from the hospital. CONCLUSIONS: With proper patient selection and careful attention to hemodynamic management, ECMO remains a reasonable treatment option for patients with COVID‐19.

lacking detailed patient information or management algorithms all while reporting excessive mortality.

Methods: Case report from a prospectively maintained institutional ECMO database for COVID-19.

Results: We describe veno-venous (VV) ECMO in a COVID-19-positive woman with hypoxic respiratory dysfunction failing mechanical ventilation support while prone and receiving inhaled pulmonary vasodilator therapy. After 9 days of complex management secondary to her hyperdynamic circulation, ECMO support was successfully weaned to supine mechanical ventilation and the patient was ultimately discharged from the hospital. concern it may worsen the illness. 2 Despite anecdotal evidence, data are limited and patient details remain sparse. 3 

Our patient is a 49-year-old woman with obesity (body mass index: 39) and hypertension who developed cough, sore throat, and fever progressing to severe dyspnea. She presented to the emergency room with a resting oxygen saturation of 75% (room air) improving to 88% via non-rebreather. Chest radiograph revealed bilateral infiltrates; attempts to obtain an arterial blood gas (ABG) were unsuccessful due to clotted samples. The patient improved on supine ventilation, was extubated, and discharged from the hospital.

Here we describe our approach to a patient with COVID-19 who failed medical management and required VV ECMO. Currently, there are no guidelines available, therefore we have formulated an algorithm for early identification of patients with COVID-19 requiring ECMO and devised management strategies to navigate their course ( Figure 1 ). We have included information on patient selection and contraindications including advanced age, malignancy, and profound F I G U R E 1 Patient selection, evaluation, and treatment strategies. ARDS, acute respiratory distress syndrome; CHF, congestive heart failure; CKD, chronic kidney disease; DO 2 , oxygen delivery; ECMO, extracorporeal membrane oxygenation; PAO 2 , partial pressure of oxygen; PCO 2 , partial pressure of carbon dioxide; PEEP, positive end-expiratory pressure; VO 2 , oxygen consumption; V/Q, ventilation/perfusion neurologic injury. This case had several challenging aspects including hyperdynamic cardiac function and coagulopathy.

COVID-19 has been associated with a hyperinflammatory state secondary to cytokine storm, manifested by inflammatory markers, vasodilatory shock, and increased CO. This high output state can be difficult to manage on ECMO due to inadequate entrainment of CO into the circuit. Previous studies reported that extracorporeal capture of at least 60% of the native CO is essential for a saturation of 90% or PAO 2 of 60 mm Hg. 4 Our patient responded well to the combination of short acting β-blockers and vasoconstrictors; however, careful hemodynamic monitoring must be maintained due to concern for cardiac dysfunction from sepsis or COVID-19-related cardiomyopathy. 5 A plan to convert to a venoarterial configuration should be considered on a case-by-case basis, and invasive hemodynamic monitoring and frequent bedside echocardiography are useful. Approaches to the management of persistent hypoxia while on ECMO support are detailed in Figure 1 .

We anticipate that weaning of VV ECMO support in the COVID-19 cohort will be challenging given the variable evolution of lung disease we have observed in our non-ECMO cases manifesting with severe hypoxic failure. Due to risks of aerosolization, we deferred tracheostomy which varies from our usual practice of early tracheostomy and reduction in sedation. Given these changes, patients with COVID-19 are at risk for deconditioning and ventilator-associated pneumonia, which may further complicate the ability to wean ECMO.

Given reports of thrombosis in patients with COVID-19, 6 we began a heparin infusion on return of abnormal laboratory values in addition to a larger bolus of heparin before cannulation to avoid these complications.

We experienced no issues with clot formation in the cannula or circuit but did experience persistent bleeding at the cannulation sites prompting a trial off ECMO. While thrombosis remains a risk, bleeding complications are significant, therefore we advise careful monitoring of coagulation studies and ECMO circuitry in this cohort.

To date, outcomes using ECMO with COVID-19 remain poor with few details on the specifics of patient characteristics, acceptance criteria, and management. Henry et al 3 published the first pooled series of patients yielding a combined ECMO mortality of 94%, hypothesizing the immunologic consequences of ECMO lead to worse outcomes. 2 Li et al 7 published a series of COVID-19 ECMO patients (n = 8) with 50% mortality. In summary, we were able to recover one COVID-19 patient with VV ECMO. With careful patient selection, mechanical support is a reasonable treatment strategy.

COVID-19, ECMO, and lymphopenia: a word of caution

Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): pooled analysis of early reports

Blood oxygenation and decarboxylation determinants during venovenous ECMO for respiratory failure in adults

Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Extracorporeal membrane oxygenation for coronavirus disease

COVID-19 patient bridged to recovery with venovenous extracorporeal membrane oxygenation

The authors declare that there are no conflict of interests.

All authors contributed to the concept, design, drafting, revision and approval of the article.

http://orcid.org/0000-0001-8304-5412